AKT3 and posterior cortical atrophy: The involvement of AKT3 in neuroendocrine differentiated PCa could be used to develop a new treatment, combining an androgen decreasing agent and an AKT inhibitor, which may enhance the health condition of patients with metastatic castration-resistant PCa.